Literature DB >> 1514686

Analysis of human synovial fluid phospholipase A2 on short chain phosphatidylcholine-mixed micelles: development of a spectrophotometric assay suitable for a microtiterplate reader.

L J Reynolds1, L L Hughes, E A Dennis.   

Abstract

The development of a reliable assay for human synovial fluid phospholipase A2 (HSF PLA2) is important for the kinetic characterization of the enzyme and for the identification of enzyme inhibitors. This enzyme behaves differently from other extracellular PLA2s in many standard phospholipase assays and is generally assayed using radiolabeled, autoclaved Escherichia coli as a substrate. We have now developed a nonradioactive, continuous, spectrophotometric assay for this enzyme that is adaptable for use with a microtiterplate reader and is suitable for screening enzyme inhibitors. The assay uses a thioester derivative of diheptanoyl phosphatidylcholine as a substrate, with which the enzyme displays a specific activity of about 25 mumol min-1 mg-1. The substrate concentration curve fits a Hill equation with an apparent Km of 500 microM and a Hill coefficient of two. The enzyme has a pH optimum of 7.5 in this assay and requires about 10 mM Ca2+ for maximal activity. The presence of 0.3 mM Triton X-100 was necessary to solubilize the substrate; however, higher concentrations of the detergent inhibited enzyme activity. Using this spectrophotometric assay, inhibition of HSF PLA2 by a thioether phosphonate phosphatidylethanolamine analog was observed with an IC50 of 18 microM.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1514686     DOI: 10.1016/0003-2697(92)90160-9

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  20 in total

1.  Protein synthesis by native chemical ligation: expanded scope by using straightforward methodology.

Authors:  T M Hackeng; J H Griffin; P E Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

2.  Total chemical synthesis of enzymatically active human type II secretory phospholipase A2.

Authors:  T M Hackeng; C M Mounier; C Bon; P E Dawson; J H Griffin; S B Kent
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

3.  Pseudolipasin A is a specific inhibitor for phospholipase A2 activity of Pseudomonas aeruginosa cytotoxin ExoU.

Authors:  Vincent T Lee; Stefan Pukatzki; Hiromi Sato; Eriya Kikawada; Anastasia A Kazimirova; Jin Huang; Xiaohua Li; Jonathan P Arm; Dara W Frank; Stephen Lory
Journal:  Infect Immun       Date:  2006-12-18       Impact factor: 3.441

4.  Role of distinct phospholipases A2 and their modulators in meconium aspiration syndrome in human neonates.

Authors:  Daniele De Luca; Angelo Minucci; Domenico Tripodi; Marco Piastra; Domenico Pietrini; Cecilia Zuppi; Giorgio Conti; Virgilio P Carnielli; Ettore Capoluongo
Journal:  Intensive Care Med       Date:  2011-05-13       Impact factor: 17.440

5.  A model for the interfacial kinetics of phospholipase D activity on long-chain lipids.

Authors:  Sheereen Majd; Erik C Yusko; Jerry Yang; David Sept; Michael Mayer
Journal:  Biophys J       Date:  2013-07-02       Impact factor: 4.033

6.  Genome sequence of a serotype M3 strain of group A Streptococcus: phage-encoded toxins, the high-virulence phenotype, and clone emergence.

Authors:  Stephen B Beres; Gail L Sylva; Kent D Barbian; Benfang Lei; Jessica S Hoff; Nicole D Mammarella; Meng-Yao Liu; James C Smoot; Stephen F Porcella; Larye D Parkins; David S Campbell; Todd M Smith; John K McCormick; Donald Y M Leung; Patrick M Schlievert; James M Musser
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-16       Impact factor: 11.205

7.  Bile acids cause secretory phospholipase A2 activity enhancement, revertible by exogenous surfactant administration.

Authors:  Daniele De Luca; Angelo Minucci; Enrico Zecca; Marco Piastra; Domenico Pietrini; Virgilio P Carnielli; Cecilia Zuppi; Ascanio Tridente; Giorgio Conti; Ettore D Capoluongo
Journal:  Intensive Care Med       Date:  2008-10-14       Impact factor: 17.440

8.  Selective inhibition of human group IIA-secreted phospholipase A2 (hGIIA) signaling reveals arachidonic acid metabolism is associated with colocalization of hGIIA to vimentin in rheumatoid synoviocytes.

Authors:  Lawrence K Lee; Katherine J Bryant; Romaric Bouveret; Pei-Wen Lei; Anthony P Duff; Stephen J Harrop; Edwin P Huang; Richard P Harvey; Michael H Gelb; Peter P Gray; Paul M Curmi; Anne M Cunningham; W Bret Church; Kieran F Scott
Journal:  J Biol Chem       Date:  2013-03-12       Impact factor: 5.157

9.  Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist.

Authors:  Thiruma V Arumugam; Naomi Arnold; Lavinia M Proctor; Michelle Newman; Robert C Reid; Karl A Hansford; David P Fairlie; Ian A Shiels; Stephen M Taylor
Journal:  Br J Pharmacol       Date:  2003-07-29       Impact factor: 8.739

10.  Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2.

Authors:  R W Schevitz; N J Bach; D G Carlson; N Y Chirgadze; D K Clawson; R D Dillard; S E Draheim; L W Hartley; N D Jones; E D Mihelich
Journal:  Nat Struct Biol       Date:  1995-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.